Valeritas to Report First Quarter 2019 Financial Results on May 9, 2019
April 22 2019 - 7:00AM
Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology
company and maker of V-Go® Wearable Insulin Delivery device, a
simple, all-in-one, wearable insulin delivery option for patients
with diabetes, today announced that it will release financial
results for the first quarter of 2019 after the close of trading on
Thursday, May 9, 2019. Valeritas’ management team will host a
corresponding conference call beginning at 4:30 p.m. ET.
Investors interested in listening to the conference call may do
so by dialing (833) 299-8115 for domestic callers or (647) 689-4542
for international callers, using Conference ID: 2596585. A live and
archived webcast of the event will be available on the “Investors”
section of Valeritas’ website at: www.valeritas.com.
About Valeritas Holdings, Inc.
Valeritas is a commercial-stage medical technology company
focused on improving health and simplifying life for people with
diabetes by developing and commercializing innovative technologies.
Valeritas’ flagship product, V-Go® Wearable Insulin Delivery
device, is a simple, affordable, all-in-one basal-bolus insulin
delivery option for patients with type 2 diabetes that is worn like
a patch and can eliminate the need for taking multiple daily shots.
V-Go administers a continuous preset basal rate of insulin over 24
hours, and it provides discreet on-demand bolus dosing at
mealtimes. It is the only basal-bolus insulin delivery device on
the market today specifically designed keeping in mind the needs of
type 2 diabetes patients. Headquartered in Bridgewater, New Jersey,
Valeritas operates its R&D functions in Marlborough,
Massachusetts.
More information is available at www.valeritas.com and our
Twitter feed @Valeritas_US, www.twitter.com/Valeritas_US.
Forward-Looking Statements
This press release may contain forward-looking statements.
Statements in this press release that are not purely historical are
forward-looking statements. Such forward-looking statements
include, among other things, references to Valeritas technologies,
business and product development plans and market information.
Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors
include, among others, the ability to raise the additional funding
needed to continue to pursue Valeritas’ business and product
development plans, the inherent uncertainties associated with
developing new products or technologies, the ability to
commercialize the V-Go® Wearable Insulin Delivery device with
limited resources, competition in the industry in which Valeritas
operates and overall market conditions. Statements or claims made
by third parties regarding the efficacy or functionality of V-Go as
compared to other products are statements made by such individual
and should not be taken as evidence of clinical trial results
supporting such statements or claims. Any forward-looking
statements are made as of the date of this press release, and
Valeritas assumes no obligation to update the forward-looking
statements or to update the reasons why actual results could differ
from those projected in the forward-looking statements, except as
required by law. Investors should consult all of the information
set forth herein and should also refer to the risk factor
disclosure set forth in the reports and other documents Valeritas
files with the SEC available at www.sec.gov.
Investor Contacts:Lynn Pieper Lewis or Greg ChodaczekGilmartin
Group646-924-1769ir@valeritas.com
Media Contact:Kevin KnightKnight Marketing Communications,
Ltd.206-451-4823pr@valeritas.com
Valeritas (NASDAQ:VLRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Valeritas (NASDAQ:VLRX)
Historical Stock Chart
From Sep 2023 to Sep 2024